Covid-19 vaccine: Sanofi will publish its final results in the first quarter of 2022, after a further delay – franceinfo

The French laboratory Sanofi now plans to publish the final results of its clinical trial on its Covid-19 vaccine during the first quarter of 2022, when they were initially expected at the end of 2021.

The group, which is developing this recombinant protein-based vaccine with the British GSK, unveiled on Wednesday, December 15, intermediate results deemed positive as a booster dose, but it does not give a precise timetable for its marketing.

“We will bring this vaccine next year. If it’s for a third dose, it will be a third dose,” explained Olivier Bogillot, President France of Sanofi. “We are no longer in a speed race. (…) We can see that the virus is here for a long time. We will have a French vaccine”, he continued.

A single booster dose of the vaccine candidate from Sanofi and GSK “made it possible to obtain strong immune responses”, argues the laboratory in a press release.

The results of this test indeed show a multiplication of the order of 9 to 43 in neutralizing antibodies, regardless of the vaccine received as a primary vaccination. In addition, the global phase 3 trial, in primary vaccination, is continuing, according to the recommendation of the Independent Committee for Surveillance and Data Monitoring, until early 2022, in order to collect more data.

The mastodon is expected, while France has so far failed to market a vaccine against Covid-19. Sanofi, one of the world leaders in non-Covid vaccines, has been widely criticized against its competitors Pfizer-BioNTech and Moderna, which launched their vaccine using messenger RNA technology as early as December 2020.